These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1269 related articles for article (PubMed ID: 12715951)
21. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma. Einsele H; Bamberg M; Budach W; Schmidberger H; Hess CF; Wörmann B; Meisner C; Straka C; Hebart H; Trümper L; Kröger N; Zander AR; Hegewisch-Becker S; Hossfeld DK; Schmidt H; Müller P; Schlimok G; Hertenstein B; Peest D; Metzner B; Frickhofen N; Kanz L; Bensinger WI Bone Marrow Transplant; 2003 Sep; 32(6):593-9. PubMed ID: 12953132 [TBL] [Abstract][Full Text] [Related]
22. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
23. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253 [TBL] [Abstract][Full Text] [Related]
24. Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma. Gertz MA; Lacy MQ; Inwards DJ; Gastineau DA; Tefferi A; Chen MG; Witzig TE; Greipp PR; Litzow MR Bone Marrow Transplant; 2000 Jul; 26(1):45-50. PubMed ID: 10918404 [TBL] [Abstract][Full Text] [Related]
25. Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. Cogle CR; Moreb JS; Leather HL; Finiewicz KJ; Khan SA; Reddy VS; Wingard JR Am J Hematol; 2003 Jul; 73(3):169-75. PubMed ID: 12827653 [TBL] [Abstract][Full Text] [Related]
26. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature]. Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442 [TBL] [Abstract][Full Text] [Related]
27. Single versus double autologous stem-cell transplantation for multiple myeloma. Attal M; Harousseau JL; Facon T; Guilhot F; Doyen C; Fuzibet JG; Monconduit M; Hulin C; Caillot D; Bouabdallah R; Voillat L; Sotto JJ; Grosbois B; Bataille R; N Engl J Med; 2003 Dec; 349(26):2495-502. PubMed ID: 14695409 [TBL] [Abstract][Full Text] [Related]
28. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P; J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936 [TBL] [Abstract][Full Text] [Related]
29. High-dose melphalan with G-CSF-stimulated whole blood rescue followed by stem cell harvesting and busulphan/cyclophosphamide with autologous stem cell transplantation in multiple myeloma. Huijgens PC; Dekker-Van Roessel HM; Jonkhoff AR; Admiraal GC; Zweegman S; Schuurhuis GJ; Ossenkoppele GJ Bone Marrow Transplant; 2001 May; 27(9):925-31. PubMed ID: 11436102 [TBL] [Abstract][Full Text] [Related]
30. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry. Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ; Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917 [TBL] [Abstract][Full Text] [Related]
31. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Magagnoli M; Castagna L; Balzarotti M; Sarina B; Timofeeva I; Bertuzzi A; Compasso S; Nozza A; Siracusano L; Santoro A Am J Hematol; 2003 Aug; 73(4):267-72. PubMed ID: 12879431 [TBL] [Abstract][Full Text] [Related]
32. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697 [TBL] [Abstract][Full Text] [Related]
33. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350 [TBL] [Abstract][Full Text] [Related]
34. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma. Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425 [TBL] [Abstract][Full Text] [Related]
35. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Hovenga S; de Wolf JT; Guikema JE; Klip H; Smit JW; Smit Sibinga CT; Bos NA; Vellenga E Bone Marrow Transplant; 2000 Apr; 25(7):723-8. PubMed ID: 10745257 [TBL] [Abstract][Full Text] [Related]
36. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
37. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment. Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875 [TBL] [Abstract][Full Text] [Related]
38. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968 [TBL] [Abstract][Full Text] [Related]
39. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy]. Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874 [TBL] [Abstract][Full Text] [Related]